Nicotine metabolism in African Americans and European Americans: Variation in glucuronidation by ethnicity and UGT2B10 haplotype

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 202-209

  Berg, Jeannette Zinggeler ^a   Mason, Jesse ^a   Boettcher, Angela J ^a   Hatsukami, Dorothy K ^a   Murphy, Sharon E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; DRUG METABOLITE; GLUCURONIDE; NICOTINE;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CATALYST; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; ETHNICITY; EUROPEAN AMERICAN; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PLASMA; PRIORITY JOURNAL; SMOKING; UGT2B10 GENE; URINE;

ADULT; AFRICAN AMERICANS; COTININE; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; NICOTINE; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 73949104432     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159855     Document Type: Article

References (39)

1. Benowitz NL (1999) Nicotine addiction. Prim Care 26:611-631.
2. Benowitz NL, Jacob P 3rd, Fong I, and Gupta S (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268:296-303.
3. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, and Jacob P 3rd (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291:1196-1203.
4. Benowitz NL, Pomerleau OF, Pomerleau CS, and Jacob P 3rd (2003) Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 5:621-624.
5. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, Sharp DJ, Eriksen MP, Pirkle JL, and Maurer KR (1998) Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. J Am Med Assoc 280:135-139.
6. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, and Lazarus P (2007) Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res 67:9024-9029.
7. Chen G, Dellinger RW, Gallagher CJ, Sun D, and Lazarus P (2008) Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 18:181-191.
8. Derby KS, Cuthrell K, Caberto C, Carmella SG, Franke AA, Hecht SS, Murphy SE, and Le Marchand L (2008) Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev 17:3526-3535.
9. Ehmer U, Vogel A, Schü tte JK, Krone B, Manns MP, and Strassburg CP (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDPglucuronosyltransferase UGT1A4. Hepatology 39:970-977.
10. Fowler BA, Kleinow KM, Squibb KS, Lucier GW, and Hayes WA (1994) Organelles as Tools in Toxicology, in Principles and Methods of Toxicology (Hayes AW ed) pp 1267-1268, Raven Press, New York.
11. Gelal A, Jacob P 3rd, Yu L, and Benowitz NL (1999) Disposition kinetics and effects of menthol. Clin Pharmacol Ther 66:128-135.
12. Hagan RL, Ramos JM Jr, and Jacob PM 3rd (1997) Increasing urinary cotinine concentrations at elevated temperatures: the role of conjugated metabolites. J Pharm Biomed Anal 16:191-197.
13. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, and Le Marchand L (2006) Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354:333-342.
14. Hecht SS, Carmella SG, and Murphy SE (1999a) Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 8:907-913.
15. Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, and Hatsukami DK (1999b) Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 59:590-596.
16. Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, Roe MR, Puumala SS, Li YS, Le C, et al. (2004) Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 96:107-115.
17. Heck JD (2009) Smokers of menthol and nonmenthol cigarettes exhibit similar levels of biomarkers of smoke exposure. Cancer Epidemiol Biomarkers Prev 18:622-629.
18. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, and Tyndale RF (2009) Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 85:635-643.
19. Hukkanen J, Jacob P 3rd, and Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79-115.
20. Jemal A (2009) Cancer Facts and Figures for African Americans 2009-2010. American Cancer Society, Atlanta, GA.
21. Kaivosaari S, Toivonen P, Aitio O, Sipilä J, Koskinen M, Salonen JS, and Finel M (2008) Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Dispos 36:1529-1537.
22. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, and Finel M (2007) Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol 72:761-768.
23. Kandel DB, Hu MC, Schaffran C, Udry JR, and Benowitz NL (2007) Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol 165:901-910.
24. Kuehl GE and Murphy SE (2003) N-Glucuronidation of nicotine and cotinine by human liver microsomes and heterologously-expressed UDP-glucuronosyltransferases. Drug Metab Dispos 31:1361-1368.
25. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, and Wiener D (2005) Genotypephenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 15:769-778.
26. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, and Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400-409.
27. Murphy SE, Link CA, Jensen J, Le C, Puumala SS, Hecht SS, Carmella SG, Losey L, and Hatsukami DK (2004) A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol Biomarkers Prev 13:1617-1623.
28. Murphy SE, Raulinaitis V, and Brown KM (2005) Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 33:1166-1173.
29. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, and Tyndale RF (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 29:679-688.
30. Mwenifumbo JC and Tyndale RF (2007) Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 8:1385-1402.
31. Pérez-Stable EJ, Herrera B, Jacob P 3rd, and Benowitz NL (1998) Nicotine metabolism and intake in black and white smokers. J Am Med Assoc 280:152-156.
32. Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, and Maurer KR (1996) Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991. J Am Med Assoc 275:1233-1240.
33. Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, Ozawa S, Kawamoto M, Kamatani N, Shirao K, et al. (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20:144-151.
34. Scherer G, Engl J, Urban M, Gilch G, Janket D, and Riedel K (2007) Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 47:171-183.
35. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, and Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-626.
36. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, and Lerman C (2007) An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 9:511-518.
37. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, and Benowitz NL (2009) Genetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics 19:388-398.
38. von Weymarn LB, Brown KM, and Murphy SE (2006) Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther 316:295-303.
39. Wagenknecht LE, Cutter GR, Haley NJ, Sidney S, Manolio TA, Hughes GH, and Jacobs DR (1990) Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am J Public Health 80:1053-1056.